Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-07-03 09:39:11 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/JCO-24-02495
文献链接: https://ascopubs.org/doi/10.1200/JCO-24-02495
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Lingfang Xia; Keqiang Zhang; Ying Tang; Guonan Zhang; Danbo Wang; Hanmei Lou; Naifu Liu; Hongping Zhang; Hongwei Chen; Ke Wang; Shuqing Wei; Li Wang; Kun Gao; Guiling Li; Huifeng Zhang; Yuanjing Hu; Weidong Zhao; Yunyan Zhang; Hong Zhu; An Lin; Jinwei Miao; Guohua Yu; Keqin Hua; Liangdan Tang; Ziling Liu; Bingzhong Zhang; Hongwei Li; Min Zheng; Xiaohong Wang; Fenghu Li; Xinfeng Yang; Huaijun Zhou; Bairong Xia; Xianfeng Zhou; Yuting Wang; Quanren Wang; Xiaohua Wu